Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Alphabet-C
GOOG
Vale SA
VALE
Alphabet-A
GOOGL
US Stock MarketDetailed Quotes
OVID Ovid Therapeutics
- 0.963
- +0.013+1.35%
Close Jan 7 16:00 ET
- 0.963
- 0.000-0.02%
Post 16:31 ET
68.40MMarket Cap-2.09P/E (TTM)
1.010High0.940Low146.19KVolume0.960Open0.950Pre Close140.28KTurnover0.31%Turnover RatioLossP/E (Static)71.01MShares4.10052wk High0.90P/B44.78MFloat Cap0.68052wk Low--Dividend TTM46.49MShs Float15.929Historical High--Div YieldTTM7.36%Amplitude0.680Historical Low0.959Avg Price1Lot Size
Ovid Therapeutics News
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
Ovid Therapeutics' OV329: Promising Safety and Efficacy Lead to Buy Rating
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Ovid Therapeutics (OVID)
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
Ovid Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Ovid Therapeutics Analyst Ratings
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
Ovid Therapeutics Analyst Ratings
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress
B.Riley Financial Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.